A Risk-Based Approach to the Use of Biological Indicators in the Development and Control of Steam-Sterilization Processes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Risk-Based Approach to the Use of Biological Indicators in the Development and Control of Steam-Sterilization Processes
Validating the sterilization process is extremely important in pharmaceutical manufacturing. The authors explore different types of sterilization processes and discuss the importance of finding the worst-case positions of loads or equipment to be sterilized and the worst-case conditions for each sterilization cycle. Biological indicators (BIs) can be used to simulate worst-case scenarios and determine the effectiveness of a particular sterilization process.


Pharmaceutical Technology


When commercially available BIs are used, the D-value should be chosen in correlation with the sterilization process. The European Pharmacopoeia defines a standard steam-sterilization process of 15 min at 121 °C. It also is specified in Ph.Eur. chapter 5.1.1 that BIs used should have a D-value that exceeds 1.5 min (13). Following Ph.Eur., it must be verified that "exposing the biological indicators to steam at 121±1 °C for 6 min leaves revivable spores, and that there is no growth of the reference microorganisms after the biological indicators have been exposed to steam at 121±1 °C for 15 min"(14).

Kill times are expressed in a more general way in USP 30: "Kill time (in minutes) = not more than (labeled D value) × (log labeled spore count per carrier + 4)". For a viable spore count of 106/carrier and a labeled D-value of 1.5 min, the kill time is easily calculated to be 15 min, identical with the Ph.Eur. standard sterilization time. Following the logic of Ph.Eur., BIs with a lower kill time than the process to be tested would not present a sufficient challenge to the standard process.

It is interesting to note that no upper limit for the D-value is mentioned in Ph.Eur. For a BI with a D-value of 2 min and a viable spore count of 106/carrier, the kill time would be 20 min, which means that occasional positives are expected to occur after 15 min of exposure. A manufacturer obtaining a positive BI after exposure usually would be considered an indication of sterilization-cycle failure, while the true reason is inappropriate resistance of the BI.

Spore suspensions. Spore suspensions form the basis for the manufacture of commercially available BIs on carriers. They are also commercially available for use in the inoculation of products and surfaces to evaluate the effect of sterilization processes and to prepare customized BIs. Spore suspensions are addressed in USP 30 as a type of BI.

The quality of commercially available spore suspensions, however, is neither addressed in ISO 11138 (12) nor is there a monograph on BI suspensions in USP (15). Typically, manufacturers certify the D-value of their suspensions when tested on paper strips. The D-value of the spores in suspension is usually different from the certified D-value. The stability of the viable spore count in suspension also is of concern. Some spore suspensions are supplied in alcoholic suspensions, and others are supplied in water. The purity of spore suspensions with regard to cell debris that may cover spores during drying is not clearly specified anywhere. There is no international standard that could be used to qualify the spore suspensions available on the market.

More questions may arise regarding the methods applied in direct inoculation of test pieces. Test pieces may have a modulating effect on spore resistance caused by the release of ions or other substances, surface roughness that may provide local shielding of spores from the access of saturated steam, or local temperature effects. Other factors are spore distribution on the inoculated surface, the accessibility of the sterilizing agent, or the adhesiveness of the spore layer. Spores may be difficult to recover from the surface of inoculated test pieces because of strong adherence that may increase during heat exposure, meaning that the determination of an initial recovered spore count is very difficult. Standardized procedures for inoculation and testing of inoculated test pieces and recovery of spores from surfaces are not available.

When product solutions are inoculated, there are questions concerning the volume of liquid used and the kinetics of heating. Is the temperature profile in the test volume a square wave, or are there shoulder conditions that must be taken into consideration?

To determine the influence of pharmaceutical preparations on the resistance and growth ability of spores, the inactivation effect during sterilization must be evaluated separately from the inhibiting effect on the growth of spores surviving after sterilization. Vice versa, the product can be influenced or altered by introducing the BI—such as in the case of the inoculation of an anhydrous product with aqueous spore suspensions.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
The Effect of Carrier Material on the Measured Resistance of Spores
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Radiation Sterilization of Parenterals
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here